Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering

Drugs · Published 2026-06-11 · DOI 10.1007/s40265-026-02348-4

Free full text

Authors (4)

Sha Li, Ying Gao, Cheng-Gang Zhu, Jian-Jun Li

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Li, S., Gao, Y., Zhu, C., et al. (2026). Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering. Drugs. https://doi.org/10.1007/s40265-026-02348-4

Related articles

• Sibeprenlimab: First Approval · Drugs · 2026 · Same journal
• The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir · Drugs · 2026 · Same journal
• Ecnoglutide: First Approvals · Drugs · 2026 · Same journal
• Etripamil: First Approval · Drugs · 2026 · Same journal
• Long-Acting Lipoglycopeptide Treatment of Invasive Gram-Positive Infections · Drugs · 2026 · Same journal
• Emerging Cardiorenal Protective Therapies in Lupus Nephritis · Drugs · 2026 · Same journal
• Reframing the High-density Lipoprotein (HDL) Hypothesis in Light of Clinical Trials of Cholesterol Ester Transfer Protein (CETP) Inhibitors · Drugs · 2026 · Same journal
• Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here · Drugs · 2026 · Same journal
• The Role of β-Blockers in the Evolving Treatment Landscape of Resistant Hypertension · Drugs · 2026 · Same journal
• Culmerciclib: First Approval · Drugs · 2026 · Same journal